The incidence rates (per 100,000) for women without cognitive impairment were 400 for the cohort aged 75 to 79 years, 412 for the cohort aged 80 to 84 years, and 388.7 for the cohort aged 85 years or older.
The life expectancies for women without cognitive impairment were 10.3 years for the cohort aged 75 to 79 years, 7.7 years for the cohort aged 80 to 84 years, and 6.6 years for the cohort aged 85 years or older.
The life expectancies for women with cognitive impairment were 4.8 years for the cohort aged 75 to 79 years, 2.2 years for the cohort aged 80 to 84 years, and 1.1 years for the cohort aged 85 years or older.
According to the breast cancer stage and the age-cohort, the 5-year survival rates for women without cognitive impairment were:
91.5% for women aged 75 to 79, 90.1% for those aged 80 to 84, and 85.2% for those aged 85 or older, among women with localised disease;
69.3% for women aged 75 to 79, 65.6% for those aged 80 to 84, and 59.8% for those aged 85 or older, among women with regional disease; and
23.4% for women aged 75 to 79, 16.6% for those aged 80 to 84, and 18.5% for those aged 85 or older, among women with distant disease.
Among women without cognitive impairment who had breast cancer, the life expectancies were:
8.7 years for women aged 75 to 79, 6.6 years for women aged 80 to 84, and 5.4 years for women aged 85 or older, if they had localised disease;
5.9 years for women aged 75 to 79, 4.7 years for women aged 80 to 84, and 3.9 years for women aged 85 or older, if they had regional disease; and
2.6 years for women aged 75 to 79, 2.0 years for women aged 80 to 84, and 2.0 years for women aged 85 or older, if they had distant disease.
The life expectancies for those women with cognitive impairment and breast cancer were:
4.4 years for those aged 75 to 79, 2.10 years for those aged 80 to 84, and 1.06 years for those aged 85 or older, if they had localised disease;
3.55 years for those aged 75 to 79, 1.89 years for those aged 80 to 85, and 0.98 for those aged 85 or older, if they had regional disease; and
2.0 years for those aged 75 to 79, 1.2 years for those aged 80 to 84, and 0.8 years for those aged 85 or older, if they had distant disease.
Among women without cognitive impairment and with breast cancer, who were screened positive, 73% had localised disease, 25% had regional disease and 2% had distant disease.
Among women without cognitive impairment and with breast cancer, who were screened false negative, 70% had localised disease and 30% had regional disease.
Among women without cognitive impairment and with breast cancer, who were not screened, 51% had localised disease, 37% had regional disease and 12% of them had distant disease.
The sensitivity for breast cancer was 0.95 and the specificity was 0.95.
The recurrence rates were 0.10 for women with localised disease, 0.80 for women with regional disease and 0.90 for women with distant disease.
These effectiveness estimators were included as key parameters in the model.